• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Beam Therapeutics Inc.

    8/7/25 11:35:12 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BEAM alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)


    Beam Therapeutics Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    07373V105

    (CUSIP Number)


    07/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    07373V105


    1Names of Reporting Persons

    ARK Investment Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    9,868,973.00
    6Shared Voting Power

    194,066.00
    7Sole Dispositive Power

    10,410,137.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,410,137.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.35 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    07373V105


    1Names of Reporting Persons

    Catherine D. Wood
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    10,063,039.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    10,410,137.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,410,137.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.35 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Beam Therapeutics Inc.
    (b)Address of issuer's principal executive offices:

    238 Main Street Cambridge, MA, 02142
    Item 2. 
    (a)Name of person filing:

    (i) ARK Investment Management LLC ("ARK") (ii) Catherine D. Wood
    (b)Address or principal business office or, if none, residence:

    ARK and Catherine D. Wood: 200 Central Avenue, St. Petersburg, FL 33701
    (c)Citizenship:

    (i) ARK: Delaware (ii) Catherine D. Wood: United States
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    07373V105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    ARK and Catherine D. Wood: 10,410,137
    (b)Percent of class:

    ARK and Catherine D. Wood: 10.35
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    (i) ARK: 9,868,973 (ii) Catherine D. Wood: 0

     (ii) Shared power to vote or to direct the vote:

    (i) ARK: 194,066 (ii) Catherine D. Wood: 10,063,039

     (iii) Sole power to dispose or to direct the disposition of:

    (i) ARK: 10,410,137 (ii) Catherine D. Wood: 0

     (iv) Shared power to dispose or to direct the disposition of:

    (i) ARK: 0 (ii) Catherine D. Wood: 10,410,137

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    No client of ARK Investment Management LLC currently has an interest in the securities reported herein in excess of 5 percent except ARK Innovation ETF, a series of a Delaware Statutory Trust.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    ARK Investment Management LLC
     
    Signature:/s/ Kellen Carter
    Name/Title:Kellen Carter, Chief Compliance Officer
    Date:08/07/2025
     
    Catherine D. Wood
     
    Signature:/s/ Catherine D. Wood
    Name/Title:Catherine D. Wood, Chief Executive Officer, Chief Investment Officer
    Date:08/07/2025
    Get the next $BEAM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BEAM

    DatePrice TargetRatingAnalyst
    3/28/2025$42.00Neutral → Buy
    BofA Securities
    3/10/2025$40.00Sector Perform → Sector Outperform
    Scotiabank
    1/29/2025Neutral → Overweight
    Cantor Fitzgerald
    11/6/2024$27.00 → $39.00Market Perform → Outperform
    Leerink Partners
    10/16/2024Sector Outperform
    Scotiabank
    7/23/2024$80.00Buy
    H.C. Wainwright
    1/29/2024$38.00 → $40.00Neutral → Overweight
    JP Morgan
    12/15/2023$35.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $BEAM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    See Remark 1 Fmr Llc sold $991,667 worth of shares (48,374 units at $20.50) (SEC Form 4)

    4 - Beam Therapeutics Inc. (0001745999) (Issuer)

    8/1/25 9:36:26 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Simon Amy sold $23,962 worth of shares (1,250 units at $19.17), decreasing direct ownership by 2% to 64,864 units (SEC Form 4)

    4 - Beam Therapeutics Inc. (0001745999) (Issuer)

    7/3/25 5:30:05 PM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Walsh Kathleen E

    4 - Beam Therapeutics Inc. (0001745999) (Issuer)

    6/6/25 4:05:30 PM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BEAM
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Beam Therapeutics Inc.

    SCHEDULE 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

    8/7/25 11:35:12 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Beam Therapeutics Inc.

    SCHEDULE 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

    8/6/25 11:51:35 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Beam Therapeutics Inc.

    10-Q - Beam Therapeutics Inc. (0001745999) (Filer)

    8/5/25 7:14:07 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BEAM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $BEAM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Beam Therapeutics upgraded by BofA Securities with a new price target

    BofA Securities upgraded Beam Therapeutics from Neutral to Buy and set a new price target of $42.00

    3/28/25 8:10:19 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Beam Therapeutics upgraded by Scotiabank with a new price target

    Scotiabank upgraded Beam Therapeutics from Sector Perform to Sector Outperform and set a new price target of $40.00

    3/10/25 11:54:09 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Beam Therapeutics upgraded by Cantor Fitzgerald

    Cantor Fitzgerald upgraded Beam Therapeutics from Neutral to Overweight

    1/29/25 7:35:38 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

    CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD). "We are thrilled that the FDA has granted RMAT designation to BEAM-101, following orphan drug designation earlier this year, reinforcing its potential as a one-time, best-in-class therapy for severe sickle cell disease," said Giuseppe Ciaramella, Ph.D., pre

    8/14/25 7:00:00 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

    With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile BEAM-302 Expanded Dose Exploration Underway in Part A and Enrollment Initiated in Part B; Data from Parts A and B of the Phase 1/2 Trial and Clinical Development Update Expected in Early 2026 Dosing Complete for 30 Sickle Cell Disease Patients and First Adolescent Patient Dosed in BEACON Phase 1/2 Trial of BEAM-101; Updated Data Expected by End of 2025 Ended Second Quarter 2025 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support O

    8/5/25 7:00:00 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

    Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Patients Required a Median of One Mobilization Cycle and Experienced Rapid Neutrophil and Platelet Engraftment Safety Profile Remained Consistent with Busulfan Conditioning, Autologous Hematopoietic Stem Cell Transplantation and Underlying SCD Enrollment Complete in Both Adult and Adolescent Cohorts of the BEACON Trial, with 30 Patients Expected to be Dosed by Mid-2025 Beam to Host Investor Webcast Today, June 13, 2025, at 4:00 p.m. ET CAMBRIDGE, Mass., June 13, 2025 (GL

    6/13/25 7:00:00 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BEAM
    Financials

    Live finance-specific insights

    View All

    Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

    Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Patients Required a Median of One Mobilization Cycle and Experienced Rapid Neutrophil and Platelet Engraftment Safety Profile Remained Consistent with Busulfan Conditioning, Autologous Hematopoietic Stem Cell Transplantation and Underlying SCD Enrollment Complete in Both Adult and Adolescent Cohorts of the BEACON Trial, with 30 Patients Expected to be Dosed by Mid-2025 Beam to Host Investor Webcast Today, June 13, 2025, at 4:00 p.m. ET CAMBRIDGE, Mass., June 13, 2025 (GL

    6/13/25 7:00:00 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

    Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evaluating Safety and Efficacy of BEAM-101 Beam to Host Investor Webcast on Friday, June 13, 2025, at 4:00 p.m. ET CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present new data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease (SCD) at the European Hematology Association 2025 Congress (EHA2025), taking place June 12-15, 2025, in Milan, Italy. BEAM-101 is an investigational ge

    5/14/25 9:30:00 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

    Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across Initial Three Dose Levels Third Dose Level of BEAM-302 (60 mg, N=3) Achieved Mean Total AAT of 12.4µM at Day 28, Exceeding Protective Therapeutic Threshold, and Reduced Mutant Z-AAT up to 78% Initial Safety Findings Demonstrated BEAM-302 was Well Tolerated at All Dose Levels with No Serious Adverse Events or Dose-Limiting Toxicities Observed Clinical Profile Supports Continued Dose Escalation, with Updated Data from Part A of the Phase 1/2 Trial Expected to be Presented at Medical Conference

    3/10/25 6:00:00 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BEAM
    Leadership Updates

    Live Leadership Updates

    View All

    Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

    CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024. Mr. Emany brings to Beam a breadth of global operational, commercial and financial experience with multinational public corporations and financial institutions. He most recently served as CFO and chief operating officer at Ironwood Pharmaceuticals, Inc. "Beam has built a strong financial position to advance our portfolio of genetic medicines, and Sravan has an exceptional background to lead our capital fo

    12/6/24 7:00:00 AM ET
    $ASRT
    $BEAM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

    CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Chirfi Guindo, chief marketing officer of Human Health at Merck & Co., Inc., to its board of directors. Mr. Guindo is a seasoned executive in the pharmaceutical industry and has been a key leader at Merck for more than 25 years, where he held senior executive roles spanning global strategy, commercial operations and leadership in healthcare solutions. "We are thrilled to welcome Chirfi to our board, bringing in yet another exceptionally talented and experienced biopharma leader to o

    12/4/24 7:00:00 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

    CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Christi Shaw to the company's board of directors. "Christi is an inspiring leader who knows firsthand what it takes to transform cutting-edge science into practice-changing commercial treatment options, most recently building and scaling the industry's premier autologous cell therapy company as CEO of Kite," said John Evans, chief executive officer of Beam Therapeutics. "Her experience leading the transformation of novel science into approved medicines, coupled with her unwavering d

    12/14/23 6:30:00 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BEAM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

    SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

    11/12/24 9:50:15 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

    SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

    11/7/24 9:56:02 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

    SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

    10/17/24 11:50:15 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care